% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

beavertail_splash 1159 posts  |  Last Activity: May 2, 2015 9:08 AM Member since: Apr 13, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • beavertail_splash by beavertail_splash Mar 5, 2015 8:40 AM Flag

    SA article; got smacked at the drop's comments (obviously a long time GERN bag holder) on Scarlet;
    "I hate to be a negative nelly, but....the list is growing:
    1) Scarlett fired Gryznov the father of imet.
    2) Scarlett sold [gave away] the stem cell business.
    3) Scarlett literally gave away GRN1005 - which we learned today just gained orphan drug fast track status.
    4) Scarlett dismantled a Nobel Prize winning lab with which he could have developed RNAi, DNAi, based on the 615 patent, for example.
    5) Scarlett sold imet to big pharma for a potential 20% share of the sales revenue, and milestone payments he will need to cover 50% of the cost of the trials he agreed to shoulder.
    6) Scarlett probably sold a bunch of valuable Geron IP (615) along with imet to j&j.
    7) Scarlett canceled the hugely successful effort in a larger ET/PV market to focus on a market of MF and tenth the size.
    8) Scarlett reduced the company to 21 employees, likely all executives, to pursue acquisition of a new drug or program or company ....he needs a year to decide which..... with the remaining cash.
    9) How about somehow running a foul of an FDA hold immediately following ASH 2013 where results of a Mayo Clinic IND trial in MF made cancer cure history.

    How's that for playing the Devil's Advocate?"
    These facts all makes sense why we're sitting in the twos with empty pockets. Non of this has added to shareholder equity.
    Considering GERN is now officially only a holding company why doesn't he use the money to buy back shares?

  • Reply to

    Partial legal victory for Geron.

    by bec38 Apr 10, 2015 10:02 PM
    beavertail_splash beavertail_splash Apr 10, 2015 11:22 PM Flag

    ...if I recall the elevated enzyme issues were noted but not considered problematic with the later dosing adjustments. The FDA eventually cleared this issue by lifting their IND hold on the drug. How could Chippy foresee their action on this issue beforehand? He stated he was surprised as was I when it happened. I doubt the plaintiff lawyers have much that will stick on this issue as well.

  • beavertail_splash beavertail_splash Mar 13, 2015 1:19 PM Flag

    Not necessarily so anymore. The FDA eased up on a lot of it's restricted (some may say gamed) procedures to allow for exceptions based on unmet needs and unique diseases needing access to a wider spectrum of treatment. This ain't your grandma's FDA anymore. We could see some special procedural approval for IMET under the UNMET needs initiative adopted recently. This change is needed if America is remain competitive with Indian & Chinese pharmas.

  • beavertail_splash beavertail_splash Mar 13, 2015 1:36 PM Flag

    INCY was possibly holding it back to maintain their multibillion market on symptomatic treatments. Although Janssen equally could have triggered something to get a better deal during a 'year' of negotiations that took place before the partnership; no one really knows because of lack of transparency with these large companies and Wall Street's hedge funds.
    HFT should be banned as should naked shorting. Not one person was held accountable for the 2008 derivative melt down so govt. enforcement is complicit in all this. The set up occurred under the republicans and the lack of enforcement of laws protecting the public from such wanton behavior has happened under the democrats. Furthermore the 90% middle & lower class is now marginalized to stretch 50% of America's wealth so that the top 10% can indulge on the other 50% of America's wealth. In 1928 the top 10% had only 27% of the total wealth and we look back on the historical distribution of wealth as outrageous back then.
    I always held the law of the pond stated all critters were equal and given equal opportunity to pursue life, health and happiness.

  • beavertail_splash beavertail_splash Feb 13, 2015 2:20 AM Flag

    should have happened last year but the FDA delayed it for a year....for no apparent reason.

  • Reply to

    New 13G Sec Filing

    by rokky44 Feb 13, 2015 1:07 PM
    beavertail_splash beavertail_splash Feb 13, 2015 2:42 PM Flag

    any share deal would be deemed as material information, subject to disclosure.

  • BOD issues themselves 1.4 mil shares worth of options
    and yet we still have no PR department
    broke down through $3.73 (20SMA)support today
    next stop $3.38
    vol was strictly due to hedge funds rotating larger tutes out of their postion here and mindless pumpers hired by them to create false expectations. Some using the vale of religion or sympathy to hide their game.
    Jkoako nor Future trader52 nor Joanie will refund your loses. Beware of forked tongued serpents in the garden of eden.

  • beavertail_splash by beavertail_splash Mar 12, 2015 12:31 AM Flag

    "We believe our current operational and financial resources, including the upfront payment received from Janssen under the Collaboration Agreement, may enable us to acquire other oncology products, programs or companies to diversify our business"

  • beavertail_splash beavertail_splash Apr 1, 2015 2:01 AM Flag

    furthermore speaking on Phil's behalf, even though neither he nor I are him, Jakafi masks the actual cancer's progression by eliminating some symptoms so it is probably more detrimental to monitor the cancer's progression especially in combo oncology treatment were advancing progression is critical to monitor and respond to. Overall it does not extend patient's overall survival time. Personally I'd just smoke a hookah pipe for symptomatic relief. THIS IS A NEGATIVE FOR JAKAFI

  • Reply to

    Partial legal victory for Geron.

    by bec38 Apr 10, 2015 10:02 PM
    beavertail_splash beavertail_splash Apr 11, 2015 4:17 PM Flag

    Sounds to me this judge, by his own admission was too lazy to write a statement explaining his decision. He dismissed the "over promotion" allegations as unfounded but left the other issue dangling about how the company may have not adequately disclosed liver enzyme issues and told the plaintiff to pursue that avenue. If he took the time to read the company's CC transcripts and the FDA's eventual turn around release decision he'd understand that these too were unfounded and that the hold was wrongfully imposed in the first place. He should have recommended the plantiff and GERO to sue the FDA. Maybe he was bought out by the INCY lobby? What's the going price for a district judge these days?

  • Reply to

    Triple Compensation?????

    by blackmarango Apr 12, 2015 10:18 PM
    beavertail_splash beavertail_splash Apr 13, 2015 6:54 PM Flag

    seriously BM do you think at this point axing Chippy would improve SP any? It's all in Janssen's hands now and perhaps without Scarlet's former J&J contacts, he wouldn't have inked the licensing deal leaving GERON open to the whims of the market hedge funds and or competitors. We don't know who else he was tangoing with last year but perhaps INCY stepped on Scarlett O'hara's toe one too many times during the bossa nova shopping the deal interlude.

  • Reply to

    So is Chippy a mole of big pharma?

    by bigmouthme Apr 22, 2015 1:51 AM
    beavertail_splash beavertail_splash Apr 22, 2015 6:42 PM Flag

    My disgust lies within Yahoo to advertise an investigation from an ambulance chasing legal firm the week after the federal district judge in California announced a partial dismissal of the previous class action suit. Yahoo never mentioned that decision and yet that was material news and this investigation isn't material only advertising for this company trying to drum up business. I hate when legal firms start impacting shareholder value. And I place partial blame on management for not addressing such concerns before these vermits (varmints that make u want to throw up) steal the show. Yahoo should be sued for freely advertising a plaintiff's request.

  • Reply to

    I wonder which hedge funds...

    by scottmayhew2000 Apr 29, 2015 2:34 PM
    beavertail_splash beavertail_splash Apr 29, 2015 4:39 PM Flag

    Mr Magoo the judge dismissed half the class action suit exonerating GERN's management in not over promoting the drug IMET. He went on to advise the plaintiff if they were to pursue the case to perhaps focus only on the toxicity issues and whether GERN's management adequately informed shareholders of potential liver issues. Without trying this case further on a message board, my sense is that management justifiably thought the liver enzyme elevations had been adequately been dealt with in the trial by tweaking dosing. Had the FDA disagreed the hold would still be in place. The second part of this case has less to stand on based on the fact the complete hold was lifted last year. No company can predict the FDA's decision wrt their drugs approval...all come with disclosed risk. The liver issues were in fact overcome as later the FDA acknowledged by lifting their previous hold.

  • Scarlet;"Although we anticipate the demands from Janssen on our clinical regulatory and manufacturing and operating teams will decrease significantly in the second half of the year.(It's already March) We plan to continue to diligently represent Geron’s interests on imetelstat joint development committee and joint steering committee as well as on several joint working group's, operating under the purview of the joint steering committee."
    ...basically GERON has become a steering committee set up to discuss whether the Cafe Zoe vendor will provide morning lattes or be replaced by Peet's Coffee & Tea. I can't believe what I read. Basically GERN has done absolutely nothing with IMET since this whole IMETELSTAT platform was handed over to Janssen last Nov. I thought Chippy was a race car driver...he hasn't even gotten IMET out of the parking garage yet after a year's delay and by the sound of dosing decisions and trial endpoints that still have to be determined; as he was still at a loss for, NOTHING, I repeat NOTHING has been done since last year's Jan conference call. And yet he gets $2.3mil worth of compensation for this? Even though a just a beaver I can't believe I got screwed into buying in this over a year ago. Promises of rainbows and pots of gold never cease to disappoint. This leprechaun has turned into a horror movie! 8=3(

  • beavertail_splash by beavertail_splash Feb 5, 2015 8:47 PM Flag

    ...two can play this game ;=3)

  • Reply to

    Sergei Gryaznov: The Geron Interview

    by kanak2k3 Feb 17, 2015 5:38 AM
    beavertail_splash beavertail_splash Feb 17, 2015 6:06 AM Flag

    Sage Sergei highlights in your interview;
    GRN 163/L Monotherapy; "Interviewer Notes: This question relates to the concept that upregulated telomerase activity is generally a late stage event in tumorogenesis. Therefore, by the time that activity can be inhibited by a molecule like GRN163/L, malignancy is already progressed and needs another drug to destroy those already-malignant cells. However, in some cancers, this activity occurs early enough that Imetelstat-like drugs can work as monotherapy."
    “615” patent very broadly describes/protects a new and highly attractive class of oligonucleotides, called 2’-arabino-fluoro N3’-P5’phosphoramidates, which could be used for various indications, as RNA targeting molecules, including, of course, as compounds designed to target telomerase RNA, and as telomerase inhibitors in general; this is as much as I can say on this matter at the moment.
    Interviewer Notes: The ‘615 patent has been of considerable interest to the Geron investors community lately, because it seems to discuss a molecule that looks like an advanced form of Imetelstat. The business aspects of that radical idea has been discussed widely in my articles and elsewhere. Dr Gryaznov’s comments here on the ‘615 patent is therefore very interesting. Interviewer Notes: The ‘615 patent has been of considerable interest to the Geron investors community lately, because it seems to discuss a molecule that looks like an advanced form of Imetelstat. The business aspects of that radical idea has been discussed widely in my articles and elsewhere. Dr Gryaznov’s comments here on the ‘615 patent is therefore very interesting."
    Phase II ear

  • Reply to

    Director sells 70k shares

    by weareinayellowsubmarine Mar 22, 2015 4:12 PM
    beavertail_splash beavertail_splash Mar 22, 2015 4:49 PM Flag

    Jokao was right, Hofastaetter's 70K worth of options were given to him several years ago exercised btwn $1.10 - $1.50/share. He sold them last week @ $4.10/share. These options also had an expiration on them so he was likely under a time limit if he was to dispose or sell them. He still holds 26.5K.

  • Reply to

    Can you hear me

    by shoenfield Mar 21, 2015 11:40 AM
    beavertail_splash beavertail_splash Mar 21, 2015 3:06 PM Flag

    So you think Janssen or even the Mayo Clinic would support such an enterprise?

  • beavertail_splash beavertail_splash Mar 25, 2015 9:51 PM Flag

    you tell em future trader49, I mean future trader 52, I mean Scottish trader 52, I mean traitor trader 666, I mean ..............

  • Reply to

    Our Geron Caldron

    by ebonymarangachachacha Mar 20, 2015 9:43 AM
    beavertail_splash beavertail_splash Mar 20, 2015 9:51 AM Flag left out my best part; dried out beaver scent glands used as a flavouring agent.
    Sheeze...some witches that think they can cook

13.63+0.0400(+0.29%)Sep 11 4:00 PMEDT